Results 121 to 130 of about 22,026 (263)

Az entero-inzularis tengely (dipeptidyl peptidase-4-incretin rendszer) jelentősége diabetesben és különböző kóros glükóztoleranciával járó állapotokban = Significance of the entero-insular axis (dipeptidyl peptidase-4–incretin system) in diabetes and in various conditions with impaired glucose tolerance [PDF]

, 2011
• Az éhomi szérum DPP-4 aktivitás nem magasabb 2-es típusú cukorbetegekben (T2DM), ha –klinikailag a nem alkoholos zsírmájbetegséget (NAFLD) a csoportból kizárjuk.
Firneisz, Gábor
core  

Real‐world treatment trajectories preceding GLP‐1 receptor agonist initiation in type 2 diabetes: A descriptive UK population‐based cohort study on adherence to national clinical guidelines

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To investigate glucose‐lowering treatment trajectories preceding glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) initiation in UK primary care, while assessing alignment with contemporary UK clinical guidelines, considering calendar time, cardiovascular disease (CVD) history, and obesity status.
Franziska S. Ulrich, Morten Frost Nielsen, Nicola Napoli, Andrea M. Burden   +3 more
wiley   +1 more source

Real‐world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes: A multi‐site retrospective study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Despite the established efficacy of tirzepatide in randomised controlled trials, real‐world effectiveness data in Japanese patients remain limited. This study evaluated the real‐world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes over 52 weeks.
Yusuke Minakata, Masaki Miura, Nobuhiro Nakatake, Masahiro Masuzawa   +3 more
wiley   +1 more source

Studi Qsar Senyawa Turunan Triazolopiperazin Amida sebagai Inhibitor Enzim Dipeptidil Peptidase-IV (DPP IV) Menggunakan Metode Semiempirik AM1 [PDF]

, 2013
Studi QSAR (Quatitative Structure-Activity Relationship) telah dilakukan untuk senyawa turunan triazolopiperazin amida sebagai inhibitor enzim DPP IV (dipeptidil peptidase-IV) yang merupakan penyebab diabetes melitus tipe 2.
Asmara, A. P. (Anjar), Mudasir, M. (Mudasir), Siswanta, D. (Dwi)   +2 more
core  

Economic burden of type 2 diabetes management in France according to clinical characteristics

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aim We sought to investigate the treatment, medication patterns, and economic burden of type 2 diabetes (T2D) in France. Materials and Methods This was a descriptive retrospective cross‐sectional study of a representative sample of adults in the national healthcare system claims database in 2022.
Bruno Guerci, Christèle Blanc‐Bisson, Eric Vicaut, Gérard De Pouvourville, Bruno Detournay, Corinne Emery, Isabelle Bureau, Taos Ihaddadene‐Salzgeber, Fleur Levrat‐Guillen, Jean‐Pierre Riveline   +9 more
wiley   +1 more source

Effectiveness and Safety of Evogliptin in Patients With Type 2 Diabetes Mellitus: A Multicenter, Prospective, Observational Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Evogliptin, a dipeptidyl peptidase‐4 inhibitor with a glucose‐dependent mechanism of action, is widely used as a monotherapy or in combination with other agents. However, observational studies in routine clinical settings remain limited.
Jun Hwa Hong, Sung Hoon Yu, Ki‐Hyun Baek, JaeMyung Yu, Seung Jin Lee, Hyung‐Wook Kim, Kang Seo Park, Jung Han Kim, KyungWan Min, Yong Hwan Lee, Koon Soon Kim, Min Soo Song, Ji Hoon Kim, Jie‐Eun Lee, Jong Chul Won   +14 more
wiley   +1 more source

Exploring the dipeptidyl peptidase-IV inhibitory potential of probiotic-fermented milk: An in vitro and in silico comprehensive investigation into peptides from milk of different farm animals

Journal of Dairy Science
: Bioactive peptides produced via enzymatic hydrolysis have been widely investigated for their dipeptidyl peptidase-IV (DPP-IV) inhibitory properties.
Priti Mudgil, Chee-Yuen Gan, Pei-Gee Yap, Ali Ali Redha, Reem H. Sultan Alsaadi, Khaja Mohteshamuddin, José E. Aguilar-Toalá, Abraham M. Vidal-Limon, Andrea M. Liceaga, Sajid Maqsood   +9 more
doaj   +1 more source

The perceptions of natural compounds against dipeptidyl peptidase 4 in diabetes: from to

Therapeutic Advances in Chronic Disease, 2019
Dipeptidyl peptidase IV (DPP-4), an incretin glucagon-like peptide-1 (GLP-1) degrading enzyme, contains two forms and it can exert various physiological functions particular in controlling blood glucose through the action of GLP-1.
Shian-Ren Lin, Chia-Hsiang Chang, May-Jwan Tsai, Henrich Cheng, Jian-Chyi Chen, Max K. Leong, Ching-Feng Weng   +6 more
doaj   +1 more source

Comparison of SGLT2 Inhibitors for New‐Onset Proteinuria Risk in Patients With Type 2 Diabetes and Preserved Kidney Function

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To compare the effects of individual SGLT2 inhibitors on preventing new‐onset proteinuria in patients with type 2 diabetes and preserved kidney function. Materials and Methods A target trial emulation was performed using commercially available databases, including health checkups and claims data, between April 1, 2014 and March 31, 2023 ...
Hiroki Nobayashi, Michihiro Satoh, Takuo Hirose, Shingo Nakayama, Yutaro Iwabe, Hideaki Hashimoto, Takahisa Murakami, Kouji Okada, Takefumi Mori, Hirohito Metoki   +9 more
wiley   +1 more source

Exploring the clinical utility of DPP-IV and SGLT2 inhibitors in papillary thyroid cancer: a literature review

Frontiers in Pharmacology
In the realm of clinical management, Papillary Thyroid Cancer (PTC) stands out as a prevalent thyroid malignancy, characterized by significant metabolic challenges, particularly in the context of carbohydrate metabolism.
Angelika Buczyńska, Maria Kościuszko, Adam Jacek Krętowski, Adam Jacek Krętowski, Anna Popławska-Kita   +4 more
doaj   +1 more source